Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,064,142 papers from all fields of science
Search
Sign In
Create Free Account
lobenzarit
Known as:
lobenzart
, 2-((2-carboxyphenyl)amino)-4-chlorobenzoic acid
, Benzoic acid, 2-((2-carboxyphenyl)amino)-4-chloro-, disodium salt
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
5 relations
Broader (4)
Anti-Inflammatory Agents, Non-Steroidal
Immunologic Adjuvants
Immunosuppressive Agents
ortho-Aminobenzoates
Narrower (1)
lobenzarit disodium
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Repurposing the Chemical Scaffold of the Anti‐Arthritic Drug Lobenzarit to Target Tryptophan Biosynthesis in Mycobacterium tuberculosis
G. Evans
,
S. Gamage
,
E. M. Bulloch
,
E. Baker
,
W. Denny
,
J. Lott
ChemBioChem
2014
Corpus ID: 10024253
The emergence of extensively drug‐resistant strains of Mycobacterium tuberculosis (Mtb) highlights the need for new therapeutics…
Expand
Highly Cited
2012
Highly Cited
2012
Identifying mechanism-of-action targets for drugs and probes
Elisabet Gregori-Puigjané
,
V. Setola
,
+6 authors
B. Shoichet
Proceedings of the National Academy of Sciences
2012
Corpus ID: 10367914
Notwithstanding their key roles in therapy and as biological probes, 7% of approved drugs are purported to have no known primary…
Expand
2007
2007
Investigation of the influence of particle size on the excipient percolation thresholds of HPMC hydrophilic matrix tablets.
A. Miranda
,
M. Millán
,
I. Caraballo
Journal of Pharmacy and Science
2007
Corpus ID: 9897683
In previous papers of our research group, a linear relationship between the drug percolation threshold and the relative drug…
Expand
1999
1999
Evaluation of Eudragit RS-PO and Ethocel 100 matrices for the controlled release of lobenzarit disodium.
A. Boza
,
I. Caraballo
,
J. Álvarez-Fuentes
,
A. Rabasco
Drug Development and Industrial Pharmacy
1999
Corpus ID: 22145091
Lobenzarit disodium is a drug for the treatment of rheumatoid arthritis. In this work, inert matrix tablets of lobenzarit…
Expand
Highly Cited
1995
Highly Cited
1995
Effect of a novel anti-rheumatic drug, TA-383, on type II collagen-induced arthritis.
M. Ueno
,
K. Imaizumi
,
T. Sugita
,
I. Takata
,
M. Takeshita
International Journal of Immunopharmacology
1995
Corpus ID: 19466872
1995
1995
IL-6-mediated MHC class II induction on RIN-5AH insulinoma cells by IFN-γ occurs via the G-protein pathway
S. Vassiliadis
,
G. Papadopoulos
Mediators of Inflammation
1995
Corpus ID: 47497225
Major histocompatibility complex (MHC) class II antigen expression has been implicated in the pathogenesis of autoimmune type 1…
Expand
1991
1991
Suppressive effect of anti-rheumatic drugs on interleukin-1 beta release from human peripheral blood monocytes.
M. Okamoto
,
M. Sasano
,
+4 authors
R. Yokohari
International Journal of Immunopharmacology
1991
Corpus ID: 20956771
1989
1989
Different inhibitory actions of immunomodulating agents and immunosuppressive agents on bone resorption of mouse calvaria.
K. Sasagawa
,
S. Fujibayashi
,
+5 authors
K. Someya
International Journal of Immunopharmacology
1989
Corpus ID: 19830603
1989
1989
Inhibition of Streptozocin-Induced Insulitis and Diabetes With Lobenzarit in CD-1 Mice
R. Iwakiri
,
S. Nagafuchi
Diabetes
1989
Corpus ID: 23063820
When multiple low doses (30 mg/kg body wt) of streptozocin were given to CD-1 mice, diabetes associated with L3T4 T-lymphocyte…
Expand
1984
1984
A multicenter double-blind controlled study of lobenzarit, a novel immunomodulator, in rheumatoid arthritis.
Y. Shiokawa
,
Y. Horiuchi
,
+7 authors
N. Ogawa
Journal of Rheumatology
1984
Corpus ID: 776889
A multicenter double-blind study was carried out in patients with rheumatoid arthritis (RA) by comparing treatment with a novel…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE